Efficacy and safety of ultra-long-acting insulin degludec

Ammar Wakil, Stephen Atkin

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control. Insulin degludec is a new generation, ultra-long-acting basal insulin that forms soluble multihexamers at the injection site that slowly release insulin degludec monomers into the circulation giving a prolonged duration of action. Insulin degludec may provide a safe and convenient dosing option for patients who require some flexibility in adhering to an insulin regimen according to their lifestyle or circumstances. In this review we focus on the early phases of insulin degludec development.

Original languageEnglish
Pages (from-to)55-59
Number of pages5
JournalTherapeutic Advances in Endocrinology and Metabolism
Volume3
Issue number2
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Long-Acting Insulin
Safety
Insulin
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Life Style
Injections
insulin degludec

Keywords

  • hypoglycaemia
  • insulin degludec
  • type 1 and type 2 diabetes
  • ultra-long-acting basal insulin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Efficacy and safety of ultra-long-acting insulin degludec. / Wakil, Ammar; Atkin, Stephen.

In: Therapeutic Advances in Endocrinology and Metabolism, Vol. 3, No. 2, 2012, p. 55-59.

Research output: Contribution to journalReview article

@article{365a8fe97c3a45969248dd088e4a2827,
title = "Efficacy and safety of ultra-long-acting insulin degludec",
abstract = "All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control. Insulin degludec is a new generation, ultra-long-acting basal insulin that forms soluble multihexamers at the injection site that slowly release insulin degludec monomers into the circulation giving a prolonged duration of action. Insulin degludec may provide a safe and convenient dosing option for patients who require some flexibility in adhering to an insulin regimen according to their lifestyle or circumstances. In this review we focus on the early phases of insulin degludec development.",
keywords = "hypoglycaemia, insulin degludec, type 1 and type 2 diabetes, ultra-long-acting basal insulin",
author = "Ammar Wakil and Stephen Atkin",
year = "2012",
doi = "10.1177/2042018812437181",
language = "English",
volume = "3",
pages = "55--59",
journal = "Therapeutic Advances in Endocrinology and Metabolism",
issn = "2042-0188",
publisher = "Sage Periodicals Press",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of ultra-long-acting insulin degludec

AU - Wakil, Ammar

AU - Atkin, Stephen

PY - 2012

Y1 - 2012

N2 - All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control. Insulin degludec is a new generation, ultra-long-acting basal insulin that forms soluble multihexamers at the injection site that slowly release insulin degludec monomers into the circulation giving a prolonged duration of action. Insulin degludec may provide a safe and convenient dosing option for patients who require some flexibility in adhering to an insulin regimen according to their lifestyle or circumstances. In this review we focus on the early phases of insulin degludec development.

AB - All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control. Insulin degludec is a new generation, ultra-long-acting basal insulin that forms soluble multihexamers at the injection site that slowly release insulin degludec monomers into the circulation giving a prolonged duration of action. Insulin degludec may provide a safe and convenient dosing option for patients who require some flexibility in adhering to an insulin regimen according to their lifestyle or circumstances. In this review we focus on the early phases of insulin degludec development.

KW - hypoglycaemia

KW - insulin degludec

KW - type 1 and type 2 diabetes

KW - ultra-long-acting basal insulin

UR - http://www.scopus.com/inward/record.url?scp=84859336766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859336766&partnerID=8YFLogxK

U2 - 10.1177/2042018812437181

DO - 10.1177/2042018812437181

M3 - Review article

VL - 3

SP - 55

EP - 59

JO - Therapeutic Advances in Endocrinology and Metabolism

JF - Therapeutic Advances in Endocrinology and Metabolism

SN - 2042-0188

IS - 2

ER -